The global Haematocrit Tests Market was valued at around US$ 4,035.6 Million at the end of 2021. The market is projected to register a 4.3 % CAGR and top a valuation of US$ 6,427.6 Million by 2032.
The global Haematocrit tests market is expanding because of the rising incidence of disorders like diabetes, cancer, cardiovascular, kidney, and other blood-related illnesses.
The haematocrit test measures the volume of red blood cells about the volume of all the blood (red blood cells and plasma). Direct measurement of this value using microhaematocrit centrifugation. Haematocrit tests are also known as HCT, packed cell volume (PCV), Haemoglobin and Haematocrit. Throughout the forecast period, significant growth is anticipated for the worldwide haematocrit test market.
Haematocrit test market growth is expected to be lucrative due to the rise in the prevalence of chronic diseases that can lead to blood problems, including cardiac disorders, kidney disorders, and others.
One of the key reasons propelling the growth of the haematocrit test devices market globally is the rising elderly population and the rise in blood-related disorders among the senior population. Additionally, the rise in anaemia cases, other chronic diseases that cause anaemia, and technological developments backed by government funding and initiatives are all expected to contribute to the market's expansion.
| Attributes | Details |
| Haematocrit tests market value in 2021 | US$ 4,035.6 Million |
| Haematocrit tests market value in 2032 | US$ 6,427.6 Million |
| Haematocrit tests market CAGR (2022 to 2032) | 4.3 % |
During the projected period, the market for haematology tests is anticipated to expand rapidly. The global market for haematology testing is expanding as a result of several factors, including the development of technologically sophisticated haematology analyzers, an increase in the use of flow cytometry in haematology testing, and the creation of high-sensitivity point-of-care haematology analyzers.
Due to the rise in blood-related disorders among COVD-infected individuals, the COVID-19 impact is anticipated to have a beneficial effect on the market. For instance, the article Anaemia predicts poor results of COVID-19 in hospitalised patients published in 2021 said that anaemia was prevalent and associated with bad outcomes of COVID-19 in hospitalised patients. As a result, there was a greater need for haematocrit test instruments among COVID-19-infected individuals due to the rising prevalence of blood-related disorders.
The increasing use of the haematocrit test, research and development activities combined with technological advancements in medical equipment, and other factors are also propelling the growth of the haematocrit test market. For instance, user-friendly point-of-care haematocrit tests, lab automation, automated sample collection, test identification, and others.
The Haematocrit tests market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
Due to the widespread use of haematocrit tests in conjunction with other diagnostic procedures and the high prevalence of chronic diseases, North America commands the lion's share of the global market for haematocrit test equipment. Anaemia is the most prevalent blood illness and affects more than 3 million Americans, according to a 2022 publication from the American society of haematology.
Companies that are involved in the production and marketing of haematology analyzers and reagents are finding new sources of income in developing markets like China, India, Brazil, and Mexico. The growing patient population, rising healthcare expenses, and an increase in medical tourism because of affordable treatments are the key factors driving the demand for haematological tests in these emerging nations.
Abbott Laboratories, Boule Diagnostics AB, Danaher Corporation, EKF Diagnostics, F. Hoffmann-La Roche Ltd., HORIBA, Ltd., Nova Biomedical, Sysmex Corporation., Siemens Healthcare GmbH, Thermo Fisher Scientific, among others.
| Report Attributes | Details |
| Growth Rate | CAGR of 4.3 % from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segment Covered |
|
| Region Covered |
|
| Key Countries Profiled |
|
| Key Players |
|
| Customization | Available Upon Request |
The USA, Canada, China, India, Brazil, and Mexico are some of the key producers of haematocrit tests across the world.
The haematocrit test market is set to witness a high growth rate of 4.3 % over the forecast period and is anticipated to be valued at the USA $ 6,427.6 Million in the year 2032.
Explore Similar Insights
Hematocrit Tests Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
